Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
A phase 1/2 trial of FPI-2265, Actinium-225 PSMA agents, Palacaparib in prostate cancer, run by AstraZeneca, now recruiting.
Overview
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT07590934 by AstraZeneca, with 152 participants planned, started 2026-06-03 and due to reach its primary completion in 2029-09-25. Interventions recorded: AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel, AZD2287 (Imaging agent). Conditions listed: Metastatic Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialTargeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
Shares FPI-2265, AstraZeneca, Prostate cancer.
- TrialStudy of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Shares Palacaparib, AstraZeneca, Prostate cancer.
- TrialFPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Shares FPI-2265, AstraZeneca, Prostate cancer.
- TrialStudy of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
Shares Docetaxel, AstraZeneca, Prostate cancer.
- TrialAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Shares FPI-2265, AstraZeneca, Prostate cancer.
- TrialAlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)
Shares Actinium-225 PSMA agents, AstraZeneca, Prostate cancer.
- TrialStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Shares Palacaparib, AstraZeneca.
- TrialPhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti
Shares Docetaxel, AstraZeneca.